Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Type:
Application
Filed:
March 26, 2019
Publication date:
September 12, 2019
Inventors:
Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Abstract: In the broadest aspect, the invention provides a composition for and a method of prophylactic and/or therapeutic treatment of a animal/mammal for any viral disease, mixed bacterial and viral infections, bacterial infections, bacterial endotoxins, bacterial exotoxins, autoimmune diseases, and cellular or humoral mediated allergic conditions that is caused by any virus that relies on the maintenance of specific calcium ion concentrations for the post ribosomal RNA synthesis processing of viral protein translation, transportation and processing of viral structural components by utilizing a therapeutic amount of a blocker selected from the group consisting of a calcium channel blocker, a metabolite thereof, a calmodulin blocker and a metabolite thereof, and a pharmaceutical acceptable diluent or carrier; and/or is caused by damage to the animal/mammal by a pathological immune response to antigens.
Abstract: Disclosed herein are methods of treating a tumor or cancer in a subject whose tumor or cancer cells express low levels of asparagine synthetase (ASNS), and compounds and compositions useful in such treatment. Also disclosed herein are methods of evaluating whether to administer a compound that inhibits glutathione production or a glutaminase inhibitor to a subject with a tumor or cancer.
Type:
Application
Filed:
October 18, 2018
Publication date:
September 12, 2019
Inventors:
Timothy HEFFERNAN, Jeffrey KOVACS, Nakia SPENCER, Christopher BRISTOW
Abstract: Provided herein are lipidic furan, pyrrole, and thiophene compounds, compositions, and methods using such compounds and compositions for the treatment of atrophic vaginitis. Specifically, the invention includes administering an effective amount of a compound of Formula I, I?, or I?, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from atrophic vaginitis.
Abstract: The invention relates to a dermatological or pharmaceutical composition comprising at least one aqueous phase and at least one fatty phase comprising one or more fatty compounds different from solvents and/or propenetrating agents of avermectin compounds and at least one active compound chosen from avermectin compounds, where the composition comprises neither solvents nor propenetrating agents of avermectin compounds. The invention relates also to the composition for use in the treatment of rosacea, of common acne, of seborrheic dermatitis, of perioral dermatitis, of acneiform rashes, of transient acantholytic dermatosis, of acne necrotica miliaris and of atopic dermatitis, and preferably for use in the treatment of rosacea. Finally, the invention relates to a method for preparing the composition.
Abstract: A nutritional supplement for increasing cognitive functioning. The supplement includes a flavonoid such as luteolin and a labdane diterpene such as forskolin. The supplement can also include one or any combination of L-phenylalanine, L-carnitine, acetyl-L-carnitine, and vitamin B6. Artichoke extract can be used as a source of luteolin. Methods of using the nutritional supplements to increase cognitive functioning are also included.
Abstract: The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.
Type:
Application
Filed:
March 28, 2019
Publication date:
September 12, 2019
Inventors:
Philippe DIOLEZ, Dominique DETAILLE, Frédéric MARIN, Olivier PETITJEAN
Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
Type:
Application
Filed:
October 26, 2017
Publication date:
September 12, 2019
Applicant:
Constellation Pharmaceuticals, Inc.
Inventors:
Francois Brucelle, Victor S. Gehling, Avinash Khanna
Abstract: The present invention concerns substituted indole derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Abstract: The present invention relates to compounds of formula (I) and pharmaceutical compositions comprising such compounds, for use for treating and/or preventing endometriosis.
Abstract: Methods for increasing the encapsulation or incorporation of Sunitinib into polymeric matrices have been developed. The resulting formulations provide for more sustained controlled release of sunitinib or its analog or a pharmaceutically acceptable salt thereof. Increased loading is achieved using an alkaline solvent system. The pharmaceutical compositions can be administered to treat or prevent a disease or disorder in or on the eye of a patient associated with vascularization, such as corneal neovascularization and acute macular degeneration. Upon administration, the sunitinib or its analog or salt is released over an extended period of time at concentrations which are high enough to produce therapeutic benefit, but low enough to avoid unacceptable levels of cytotoxicity.
Type:
Application
Filed:
March 18, 2019
Publication date:
September 12, 2019
Inventors:
Jie Fu, Justin Hanes, Joshua Kays, Yun Yu, Ming Yang, Jeffrey Cleland, Walter Stark, Qingguo Xu, Jin Yang
Abstract: Disclosed herein is a method against influenza A viral infection, including administering to a subject in need thereof tryptophan and arginine.
Type:
Application
Filed:
August 3, 2018
Publication date:
September 12, 2019
Inventors:
Chia-Ni LIN, Ching-Hwa TSAI, Sue-Jane LIN
Abstract: Provided herein are compositions for treating liver inflammation. The compositions include a biologically active phosphodiesterase 4 (PDE4) inhibitor and a liposome, the liposome encapsulating the PDE4 inhibitor. The liposome may be anionic and include both neutrally charged and negatively charged phospholipids. Encapsulation of the PDE4 inhibitor in the liposome facilitates targeted delivery to the liver while limiting access to the central nervous system.
Type:
Application
Filed:
November 8, 2017
Publication date:
September 12, 2019
Inventors:
Claudio Maldonado, Craig McClain, Shirish S. Barve, Leila Gobejishvili, Philip Bauer
Abstract: The disclosure herein provides combination therapies for the treatment of cancers such as Leukemia, lymphoma and triple negative breast cancer. The disclosure provides combination therapies of CDK inhibitors, e.g., a CDK inhibitor represented by Formula (I): or a pharmaceutically acceptable salt thereof together with a BCL-2 inhibitor or proteasome inhibitor for the treatment of cancer.
Abstract: The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667), or a pharmaceutically acceptable salt thereof. The methods described herein can also ameliorate complications associated with osteochondroma formation and growth in a subject with MO.
Type:
Application
Filed:
November 16, 2017
Publication date:
September 12, 2019
Inventors:
Isabelle LEMIRE, Michael HARVEY, Donna Roy GROGAN, Clarissa DESJARDINS
Abstract: The present invention provides an oral self micro-emulsifying pharmaceutical composition of a hydrophilic drug or a pharmaceutically acceptable salt thereof which, in addition to the hydrophilic drug, one or more solvents for solving the hydrophilic drug to form a drug-solvent solution and a surfactant system, further comprises one or more hydrophilic carrier which are compatible with said drug-solvent solution and the surfactant system. The oral self micro-emulsifying pharmaceutical composition of the invention exhibits comparative bioavailability to that of the hydrophilic drug through injection and is stable during storage. A method for preparing the oral self micro-emulsifying pharmaceutical composition is also provided.
Type:
Application
Filed:
May 23, 2019
Publication date:
September 12, 2019
Applicant:
INNOPHARMAX, INC.
Inventors:
Chang-Shan HSU, Wei-Hua HAO, Jong-Jing WANG, Tsung-Hsin LIN
Abstract: The present invention describes compositions, including pharmaceutical compositions, comprising an agent that binds members of the TNFRSF and a benzamide compound and methods for use thereof, for example in the treatment of cancer. In some implementations, the methods for use include methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Type:
Application
Filed:
November 24, 2017
Publication date:
September 12, 2019
Inventors:
Tong Wang, Stephen Gately, Paul Gonzales
Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
Type:
Application
Filed:
November 3, 2017
Publication date:
September 12, 2019
Applicant:
AMGEN INC.
Inventors:
Matthew BROWN, Ning CHEN, Xiaoqi CHEN, Yinhong CHEN, Alan C. CHENG, Richard V. CONNORS, Jeffrey DEIGNAN, Paul John DRANSFIELD, Xiaohui DU, Zice FU, James S. HARVEY, Julie Anne HEATH, Lars V. HEUMANN, Jonathan HOUZE, Frank KAYSER, Aarif Yusuf KHAKOO, David j. KOPECKY, Su-Jen LAI, Zhihua MA, Julio C. MEDINA, Jeffrey T. MIHALIC, Steven H. OLSON, Vatee PATTAROPONG, Gayathri SWAMINATH, Xiaodong WANG, Malgorzata WANSKA, Wen-Chen YEH
Abstract: Compounds of formula I and their metabolites are potent mediators of an inflammatory response: where a, b, c, d, e, f, V, W, X, Y, Ra, Rb, Rb?, Rc, and Rc? are defined herein. In particular, the compounds of the invention are candidate therapeutics for treating inflammatory conditions.
Type:
Application
Filed:
January 3, 2019
Publication date:
September 12, 2019
Applicant:
University of Pittsburgh - Of the Commonwealth System of Higher Education
Inventors:
Bruce A. Freeman, Francisco J. Schopfer
Abstract: A synergistic pharmaceutical composition for simultaneous, parallel, sequential or separate use comprising a thiazole and a secosteroid. The composition has utility in the treatment and prevention of skin disorders.
Type:
Application
Filed:
November 3, 2017
Publication date:
September 12, 2019
Applicants:
Avexxin AS, Avexxin AS
Inventors:
Berit Johansen, Astrid Jullumstrø Feuerherm
Abstract: A method of cancer intervention or eradication by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. The formulated drug can also be administered together with one or more of other cancer therapeutic agents. A maintenance dosing is provided after the subject is free of cancer to insure the cancer eradication. Subjects with cancers of prostate, liver, lung, ovarian, and breast are preferably accepted for treatment.
Abstract: Disclosed are compounds of the general formula (I), wherein R1-R3 are as defined herein, for use as MALT1 inhibitors in the treatment of autoimmune and inflammatory diseases or disorders. Methods of synthesizing the compounds are also disclosed. Also disclosed are pharmaceutical compositions containing a compound of the invention and a method of treating a patient for an autoimmune or an inflammatory disease or disorder, for example, a cancer, by administering a compound of the invention.
Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula: wherein R1, R2, R3, R5, R6, R8, M1, M2, M3, M4, M5, M6 and M7 are each independently a member selected from the group consisting of H, C1-6 alkyl, OH and C1-6 hydroxyalkyl; R4, R7 and R9 are each independently selected from the group consisting of C1-6 alkoxy and OH; R10 is a member selected from the group consisting of H, —OH, —OP(O)Me2, —O—(CH2)n—OH and —O—(CH2)m—O—(CH2)o—CH3, wherein subscripts n and m are each independently from 2 to 8 and subscript o is from 1 to 6; each of L1 and L4 are independently selected from the group consisting of: wherein each M8 is independently a member selected from the group consisting of C1-6 alkyl, OH and C1-6 hydroxyalkyl; each of L2 and L3 are independently selected from the group consisting of: and salts, hydrates, isomers, metabolites, N-oxides and prodrugs thereof.
Type:
Application
Filed:
October 8, 2018
Publication date:
September 12, 2019
Applicant:
Elixir Medical Corporation
Inventors:
John Yan, Xiaoxia Zheng, Vinayak D. Bhat
Abstract: A method of promoting neuroprotection in a subject from axonal degeneration, neuronal cell death, and/or glia cell damage after injury, augmenting neuronal signaling underlying learning and memory, stimulating neuronal regeneration after injury, and/or treating a disease, disorder, and/or condition of the nervous system in a subject in need thereof includes administering to the subject a therapeutically effective amount of a 15-PGDH inhibitor.
Type:
Application
Filed:
July 18, 2017
Publication date:
September 12, 2019
Applicants:
Case Western Reserve University, University of Texas Southwestern Medical Center, University of Iowa Research Foundation
Inventors:
Sanford MARKOWITZ, Joseph READY, Andrew PIEPER
Abstract: The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
Abstract: A compound of formula (I): being 4-(3-Fluoro-3-(2-(5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-2-yl) ethyl) pyrrolidin-1-yl)-3-(3-(2-methoxyethoxy) phenyl) butanoic acid, or a salt thereof.
Type:
Application
Filed:
May 28, 2019
Publication date:
September 12, 2019
Inventors:
Niall Andrew ANDERSON, Matthew Howard James CAMPBELL-CRAWFORD, Ashley Paul HANCOCK, John Martin PRITCHARD, Joanna Mary REDMOND
Abstract: The invention relates to a method of treating or preventing Parkinson's disease in a subject comprising administering a compound of Formula I wherein, R1 is —NHC(O) C3-6 cycloalkyl and R2 is hydrogen; or R1 and R2 along with the carbon atoms to which they are attached form a six membered aromatic ring, wherein the ring is substituted with one or more groups selected from hydrogen, halogen and C1-6 alkyl; R3 and R4 are independently selected from group comprising hydrogen, halogen, C1-3 alkyl, OC1-3 alkyl, NO2, SC1-3, alkyl, C1-3, haloalkyl, OC1-3 haloalkyl, and SC1-3 haloalkyl; or a pharmaceutically acceptable salt thereof.
Type:
Application
Filed:
June 2, 2017
Publication date:
September 12, 2019
Applicant:
SUN PHARMA ADVANCED RESEARCH COMPANY LTD.
Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
Type:
Application
Filed:
May 6, 2019
Publication date:
September 12, 2019
Applicant:
XSPRAY MICROPARTICLES AB
Inventors:
Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
Abstract: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
Type:
Application
Filed:
May 6, 2019
Publication date:
September 12, 2019
Applicant:
XSPRAY MICROPARTICLES AB
Inventors:
Magnus BRISANDER, Mustafa DEMIRBÜKER, Gérald JESSON, Martin MALMSTEN, Helene DÉRAND
Abstract: Provided herein are methods of increasing mucus clearance in a subject having decreased mucus clearance. Also provided are methods of treating or preventing a respiratory disorder.
Type:
Application
Filed:
September 29, 2017
Publication date:
September 12, 2019
Inventors:
Sammeta Vamsee Raju, Lawrence Rasmussen, Steven Mark Rowe
Abstract: A combination of a VEGFR inhibitor and a PARP inhibitor is described. In particular, this combination can be used in the preparation of a medicament for treating gastric cancer.
Type:
Application
Filed:
November 30, 2017
Publication date:
September 12, 2019
Applicants:
Jiangsu Hengrui Medicine Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
Abstract: The present invention relates to: an oral tablet composition comprising amorphous dexlansoprazole, mannitol having an average particle size of 100 to 400 ?m, a disintegrating agent and a lubricant; an oral tablet comprising same; and a method for manufacturing same. The oral tablet composition, according to the present invention, exhibits excellent hardness, has a shortened disintegration time, and at the same time, may be used to provide an oral tablet having improved friability. In addition, according to the present invention, a dry direct compression method is used as the method for manufacturing the oral tablet, and thus an increase in production efficiency by simplifying the production process may be achieved.
Type:
Application
Filed:
May 10, 2017
Publication date:
September 12, 2019
Applicant:
LOTTE FINE CHEMICAL CO., LTD.
Inventors:
Kwang Il Shin, Kyung Yeol Park, Sang Youb Lee
Abstract: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
Type:
Application
Filed:
April 26, 2019
Publication date:
September 12, 2019
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginnetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
Abstract: Novel combination therapies involving nitroxoline, its analogue or pharmaceutically acceptable salt thereof with at least one additional anti-cancer chemotherapy or immunotherapy agent are described. Related kits, pharmaceutical compositions and methods of production arlinee also described.
Abstract: The present invention relates to a pharmaceutical composition comprising lenvatinib mesylate and a stabilizer in an amount of about 10% to about 20% based on the total weight of the composition, wherein the stabilizer is selected from the group consisting of calcium hydroxide and potassium hydroxide; and its process for preparation thereof.
Abstract: Bis-benzyl-tetrahydroisoquinoline analogs that are derivatives of the cyclic products tetrandrine (TETN) and cepharanthine (CEPH). The analogs indicate activity against filovirus infections, including the type species Marburg virus (MARV) and Ebola virus (EBOV).
Type:
Application
Filed:
March 9, 2018
Publication date:
September 12, 2019
Inventors:
William E. BAUTA, Jonathan A. BOHMANN, Michael W. TIDWELL, Andrey D. MALAKHOV, Alejandro SANTILLAN, JR.
Abstract: Provided are NHE3-binding and/or NHE3-modulating agents having activity as phosphate transport inhibitors, including inhibitors of phosphate transport in the gastrointestinal tract and the kidneys, and methods for their use as therapeutic or prophylactic agent.
Type:
Application
Filed:
March 12, 2019
Publication date:
September 12, 2019
Applicant:
Ardelyx, Inc.
Inventors:
Christopher Carreras, Dominique Charmot, Jeffrey W. Jacobs, Eric Labonte, Jason G. Lewis
Abstract: The present invention relates to methods and compositions for treating pain in a subject and safely transitioning a subject from a full ?-opioid receptor agonist to a partial ?-opioid receptor agonist.
Type:
Application
Filed:
March 15, 2019
Publication date:
September 12, 2019
Applicant:
BioDelivery Sciences International, Inc.
Inventors:
Andrew Finn, Todd Kirby, Lynn R. Webster
Abstract: Pharmaceutical compositions and methods for treating depression, anxiety, and neurodegenerative diseases and cognitive disorders, such as dementia and Alzheimer's disease, by administering same are provided. The compositions comprise dextromethorphan in combination with quinidine.
Abstract: The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.
Type:
Application
Filed:
September 6, 2018
Publication date:
September 12, 2019
Inventors:
Thomas CHEN, Daniel LEVIN, Satish PUPALLI
Abstract: The invention relates to a method for treating idiopathic pulmonary fibrosis using a compound selected from the group consisting of nintedanib, or a pharmaceutically acceptable salt thereof, and pirfenidone, or a pharmaceutically acceptable salt thereof.
Abstract: Disclosed is a method for treatment of idiopatic pulmonary fibrosis and progressive fibrosing interstitial lung disease (PF-ILD). In one embodiment, the method of the invention comprises administering nintedanib, or pharmaceutical acceptable salt thereof, and pirfenidone, or a pharmaceutical acceptable salt thereof to a patient in need thereof.
Abstract: A method for preventing and/or treating fibrosis associated with an eye-related disease or disorder includes administering an effective amount of a multikinase inhibitor to a subject in need thereof. The multikinase inhibitor is nintedanib, lenvatinib, a combination thereof, or a salt thereof. The eye-related disease or disorder is corneal transparency, corneal scar formation, secondary cataract formation, glaucoma filtration surgery, ocular surgical procedures and implants, photorefractive keratectomy, laser in situ keratomileusis, formation and contraction of pre- and epiretinal membranes, proliferative vitreoretinopathy, subretinal fibrosis/scarring, retinal gliosis, or formation of choroidal membranes.
Type:
Application
Filed:
July 21, 2017
Publication date:
September 12, 2019
Inventors:
Diane TANG-LIU, Gerald Woodrow DEVRIES, Tiffany Constance LIU
Abstract: The present invention relates to the treatment of myocardial infarction, especially to the reduction of tissue damage, the reduction of infarction scars, the improvement of cardiac function, and/or the prevention of congestive heart failure after myocardial infarction. The invention further relates to WNT antagonists, their use in the treatment of myocardial infarction, and to pharmaceutical compositions comprising WNT antagonists.
Type:
Application
Filed:
November 6, 2017
Publication date:
September 12, 2019
Applicant:
RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG
Inventors:
Sören MEYER, Florian LEUSCHNER, Hugo KATUS
Abstract: Presented herein are powder formulations comprising dihydroergotamine (DHE), or a pharmaceutically acceptable salt thereof. In addition to such formulations, also presented herein are methods comprising intranasally administering powder formulations comprising dihydroergotamine, or a pharmaceutically acceptable salt thereof. The presented methods can be used for treating headache, for example, for rapid onset treatment of headache, including migraine, e.g. acute treatment of migraine with or without aura.
Type:
Application
Filed:
May 16, 2019
Publication date:
September 12, 2019
Inventors:
Shunji Haruta, Nikhilesh N. Singh, John Kollins, Salvador Rico
Abstract: The invention relates to methods of treating cancer or myeloproliferative diseaseswith a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
Type:
Application
Filed:
March 14, 2019
Publication date:
September 12, 2019
Inventors:
Francesco Parlati, Keith Orford, Sam H. Whiting
Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof wherein X1, X2, R1, R2, R3 and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula (I) compounds as well as methods for utilizing the compounds of Formula (I) and the pharmaceutically acceptable compositions of Formula (I) compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.
Type:
Application
Filed:
December 27, 2018
Publication date:
September 12, 2019
Inventors:
Justin T. Ernst, Paul A. Sprengeler, Siegfried H. Reich, Samuel Sperry